| Innovate Biopharmaceuticals a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. Co.'s pipeline includes drug candidates for celiac disease, nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis, Crohn's disease and ulcerative colitis (UC). Co.'s key program, INN-202 (larazotide acetate or larazotide) is entering Phase 3 registration trials for celiac disease. Co. is also developing larazotide for the treatment of NASH (INN-217), a smaller subset of liver disease stemming from the fatty liver disease. INN-108 is an oral small molecule therapeutic for UC. Co. owns the global rights to INN-329, a key formulation of secretin. We show 10 historical shares outstanding datapoints in our INNT shares outstanding history coverage, used to compute INNT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing INNT market cap history over the course of time is important for investors
interested in comparing INNT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of INNT versus a peer is one thing; comparing
INNT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like INNT can fluctuate over the course of history.
With this page we aim to empower investors researching INNT by allowing them to research the INNT market cap history.